<!DOCTYPE html>
<html lang="it">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Gestione Dolore Neuropatico - Schema Clinico</title>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mermaid/10.6.1/mermaid.min.js"></script>
    <style>
        * { box-sizing: border-box; }
        body {
            font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
            margin: 0;
            padding: 4px;
            background: white;
            color: #333;
            line-height: 1.2;
        }
        .container { max-width: 800px; margin: 0 auto; background: white; }
        .header {
            background: #2c3e50;
            color: white;
            padding: 8px;
            text-align: center;
            font-weight: bold;
            font-size: clamp(12px, 4vw, 18px);
            margin-bottom: 8px;
            border-radius: 4px;
        }
        .section {
            margin-bottom: 8px;
            border: 1px solid #ddd;
            border-radius: 6px;
            overflow: hidden;
            box-shadow: 0 2px 4px rgba(0,0,0,0.1);
            padding: 8px;
        }
        .subsection {
            margin-bottom: 6px;
            padding-left: 10px;
            border-left: 3px solid #3498db;
        }
        .table-container {
            overflow-x: auto;
        }
        table {
            width: 100%;
            border-collapse: collapse;
            font-size: clamp(9px, 3vw, 12px);
        }
        th, td {
            border: 1px solid #ddd;
            padding: 4px;
            text-align: left;
        }
        th {
            background: #f2f2f2;
        }
        .mermaid {
            text-align: center;
            margin: 10px 0;
        }
        .alert-box {
            background: #fff3cd;
            border: 1px solid #ffeaa7;
            border-radius: 4px;
            padding: 6px;
            margin: 6px 0;
            border-left: 3px solid #f39c12;
            font-size: clamp(9px, 3vw, 11px);
        }
        .alert-box.danger {
            background: #f8d7da;
            border-color: #f5c6cb;
            border-left-color: #e74c3c;
        }
        .alert-box.success {
            background: #d4edda;
            border-color: #c3e6cb;
            border-left-color: #27ae60;
        }
        .drug-card {
            background: #f8f9fa;
            border-left: 4px solid #27ae60;
            padding: 8px;
            margin: 6px 0;
            border-radius: 4px;
        }
        .drug-card.second-line { border-left-color: #f39c12; }
        .drug-card.third-line { border-left-color: #e74c3c; }
        .drug-name {
            font-weight: bold;
            font-size: clamp(11px, 3.5vw, 14px);
            color: #2c3e50;
            margin-bottom: 4px;
        }
        .scale-box {
            background: #e8f4fd;
            border: 1px solid #3498db;
            border-radius: 4px;
            padding: 8px;
            margin: 6px 0;
        }
        .classification-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 8px;
            margin: 8px 0;
        }
        .neuropathy-card {
            background: #f8f9fa;
            border-top: 3px solid #3498db;
            border-radius: 4px;
            padding: 8px;
            font-size: clamp(9px, 3vw, 11px);
        }
        .neuropathy-card h4 {
            margin: 0 0 4px 0;
            color: #2c3e50;
            font-size: clamp(10px, 3.5vw, 12px);
        }
        .guidelines-section {
            background: #f8f9fa;
            border-radius: 4px;
            padding: 8px;
            margin: 6px 0;
            border-left: 3px solid #34495e;
        }
        .back-link {
            text-align: center;
            margin-top: 20px;
            padding-top: 10px;
            border-top: 1px solid #e9ecef;
        }
        .back-link a {
            color: #3498db;
            text-decoration: none;
            font-size: 1.1em;
            font-weight: bold;
        }
        .contatti {
            text-align: center;
            margin-top: 15px;
            padding: 10px;
            border-top: 1px solid #e9ecef;
            font-size: clamp(9px, 3vw, 12px);
        }
        .social-links {
            display: flex;
            justify-content: center;
            gap: 10px;
            margin-top: 8px;
        }
        .social-link {
            display: flex;
            flex-direction: column;
            align-items: center;
            color: #333;
            text-decoration: none;
            font-size: clamp(8px, 2.5vw, 10px);
        }
        .social-link svg { width: 24px; height: 24px; }
        
        /* Ottimizzazioni specifiche per dispositivi molto piccoli */
        @media (max-width: 375px) {
            body { padding: 2px; }
            .section { padding: 6px; }
            .classification-grid { grid-template-columns: 1fr; }
        }
    </style>
</head>
<body>
    <!-- Link di ritorno e contatti -->
        <div class="back-link">
            <a href="../index.html">‚Üê Torna all'indice principale</a>
        </div>
    <div class="container">
        <div class="header">Gestione Dolore Neuropatico - Evidence Based</div>
        
        <!-- Algoritmo Decisionale Principale -->
        <div class="section">
            <h3 style="margin: 0 0 8px 0; color: #2c3e50;">üîπ Algoritmo Decisionale</h3>
            <div class="mermaid">
                flowchart TD
                    A[Diagnosi Dolore Neuropatico<br/>DN4 ‚â•4, painDETECT ‚â•19] --> B{Intensit√† NRS}
                    B -->|1-3<br/>Lieve| C[Gabapentin 300mg/die<br/>+ Approccio non farmacologico]
                    B -->|4-6<br/>Moderato| D[PRIMA LINEA]
                    B -->|7-10<br/>Severo| E[PRIMA LINEA<br/>+ Valutazione combinata]
                    
                    D --> F{Tipo}
                    E --> F
                    
                    F -->|Diabetica| G[Pregabalin 75mg bid<br/>Duloxetina 30mg/die]
                    F -->|Post-erpetica| H[Pregabalin 75mg bid<br/>Gabapentin 300mg tid]
                    F -->|Chemio| I[Duloxetina 30mg/die]
                    F -->|Trigemino| J[Carbamazepina 200mg bid]
                    
                    G --> K{Risposta 4-6 sett?}
                    H --> K
                    I --> K
                    J --> K
                    
                    K -->|Efficace ‚â•30%| L[Continuare]
                    K -->|Parziale 15-29%| M[Ottimizzare dose<br/>o Combinare]
                    K -->|Inefficace <15%| N[SECONDA LINEA]
                    
                    N --> O[Amitriptilina 25mg<br/>Capsaicina 8%<br/>Lidocaina 5%]
                    O --> P{Risposta?}
                    P -->|No| Q[TERZA LINEA<br/>Centro specialistico]
                    
                    style A fill:#e1f5fe
                    style D fill:#c8e6c9
                    style N fill:#fff3e0
                    style Q fill:#ffebee
            </div>
        </div>

        <!-- Classificazione e Approccio per Tipo -->
        <div class="section">
            <h3 style="margin: 0 0 8px 0; color: #2c3e50;">üîπ Classificazione per Tipo</h3>
            <div class="classification-grid">
                <div class="neuropathy-card">
                    <h4>üî∏ Neuropatia Diabetica</h4>
                    <p><strong>Prevalenza:</strong> 60-90% diabetici<br>
                    <strong>Prima scelta:</strong> Pregabalin, Duloxetina<br>
                    <strong>Note:</strong> Controllo glicemico fondamentale</p>
                </div>
                
                <div class="neuropathy-card">
                    <h4>üî∏ Nevralgia Post-Erpetica</h4>
                    <p><strong>Definizione:</strong> Dolore >3 mesi post-zoster<br>
                    <strong>Prima scelta:</strong> Pregabalin, Gabapentin<br>
                    <strong>Topici:</strong> Lidocaina 5%, Capsaicina 8%</p>
                </div>
                
                <div class="neuropathy-card">
                    <h4>üî∏ Neuropatia Chemio-Indotta</h4>
                    <p><strong>Agenti:</strong> Platino, Taxani<br>
                    <strong>Prima scelta:</strong> Duloxetina (evidenze pi√π forti)<br>
                    <strong>Note:</strong> Prevenzione durante chemio</p>
                </div>
                
                <div class="neuropathy-card">
                    <h4>üî∏ Nevralgia Trigemino</h4>
                    <p><strong>Caratteristiche:</strong> Dolore lancinante<br>
                    <strong>Prima scelta:</strong> Carbamazepina 200-400mg bid<br>
                    <strong>Note:</strong> Valutare chirurgia se refrattaria</p>
                </div>
            </div>
        </div>

        <!-- Farmaci Prima Linea -->
        <div class="section">
            <h3 style="margin: 0 0 8px 0; color: #27ae60;">üîπ PRIMA LINEA - Farmaci</h3>
            
            <div class="drug-card">
                <div class="drug-name">PREGABALIN</div>
                <p><strong>Meccanismo:</strong> Modulatore canali calcio (Œ±2Œ¥-1)</p>
                <div class="table-container">
                    <table>
                        <tr><th>Periodo</th><th>Dose</th><th>Frequenza</th></tr>
                        <tr><td>Giorni 1-3</td><td>75 mg</td><td>2x/die</td></tr>
                        <tr><td>Giorni 4-7</td><td>150 mg</td><td>2x/die</td></tr>
                        <tr><td>Settimana 2+</td><td>300 mg</td><td>2x/die</td></tr>
                        <tr><td>Max (se necessario)</td><td>600 mg</td><td>2x/die</td></tr>
                    </table>
                </div>
                <div class="alert-box">
                    <strong>Aggiustamento renale:</strong> GFR 30-60: -50% | GFR <30: -75%
                </div>
            </div>

            <div class="drug-card">
                <div class="drug-name">GABAPENTIN</div>
                <p><strong>Meccanismo:</strong> Modulatore canali calcio (Œ±2Œ¥-1)</p>
                <div class="table-container">
                    <table>
                        <tr><th>Settimana</th><th>Dose</th><th>Frequenza</th><th>Tot/die</th></tr>
                        <tr><td>1</td><td>300 mg</td><td>1x sera</td><td>300 mg</td></tr>
                        <tr><td>2</td><td>300 mg</td><td>2x/die</td><td>600 mg</td></tr>
                        <tr><td>3</td><td>300 mg</td><td>3x/die</td><td>900 mg</td></tr>
                        <tr><td>4+</td><td>600-1200 mg</td><td>3x/die</td><td>1800-3600 mg</td></tr>
                    </table>
                </div>
            </div>

            <div class="drug-card">
                <div class="drug-name">DULOXETINA</div>
                <p><strong>Meccanismo:</strong> SNRI (serotonina-noradrenalina)</p>
                <div class="table-container">
                    <table>
                        <tr><th>Settimana</th><th>Dose</th><th>Note</th></tr>
                        <tr><td>1-2</td><td>30 mg/die mattina</td><td>Titolazione</td></tr>
                        <tr><td>3+</td><td>60 mg/die mattina</td><td>Dose standard</td></tr>
                        <tr><td>Max</td><td>120 mg/die</td><td>Se necessario</td></tr>
                    </table>
                </div>
                <div class="alert-box danger">
                    <strong>Controindicazioni:</strong> IMAO, epatopatia severa, glaucoma
                </div>
            </div>
        </div>

        <!-- Farmaci Seconda e Terza Linea -->
        <div class="section">
            <h3 style="margin: 0 0 8px 0; color: #f39c12;">üîπ SECONDA LINEA</h3>
            
            <div class="drug-card second-line">
                <div class="drug-name">AMITRIPTILINA</div>
                <p><strong>Dose:</strong> 10-25mg sera ‚Üí 75-150mg sera<br>
                <strong>Note:</strong> Attenzione anziani, cardiopatici</p>
            </div>

            <div class="drug-card second-line">
                <div class="drug-name">CAPSAICINA TOPICA 8%</div>
                <p><strong>Applicazione:</strong> Patch 30-60 min ogni 90 giorni<br>
                <strong>Indicazioni:</strong> Nevralgia post-erpetica, HIV</p>
            </div>

            <h3 style="margin: 16px 0 8px 0; color: #e74c3c;">üîπ TERZA LINEA</h3>
            
            <div class="drug-card third-line">
                <div class="drug-name">TRAMADOLO</div>
                <p><strong>Dose:</strong> 50mg x2/die ‚Üí max 400mg/die<br>
                <strong>Rischi:</strong> Dipendenza, interazioni SSRI/SNRI</p>
            </div>
        </div>

        <!-- Efficacia e Monitoraggio -->
        <div class="section">
            <h3 style="margin: 0 0 8px 0; color: #2c3e50;">üîπ Efficacia e Monitoraggio</h3>
            
            <div class="subsection">
                <h4 style="margin: 0 0 4px 0;">NNT (Number Needed to Treat)</h4>
                <div class="table-container">
                    <table>
                        <tr><th>Farmaco</th><th>NNT</th><th>Riduzione 50%</th></tr>
                        <tr><td>Duloxetina</td><td>6.4</td><td>40-45% pazienti</td></tr>
                        <tr><td>Gabapentin</td><td>7.2</td><td>30-35% pazienti</td></tr>
                        <tr><td>Pregabalin</td><td>7.7</td><td>35-40% pazienti</td></tr>
                        <tr><td>Amitriptilina</td><td>6.8</td><td>30-40% pazienti</td></tr>
                    </table>
                </div>
            </div>

            <div class="subsection">
                <h4 style="margin: 0 0 4px 0;">Timeline Valutazione</h4>
                <div class="table-container">
                    <table>
                        <tr><th>Tempo</th><th>Valutazione</th><th>Azione</th></tr>
                        <tr><td>2 settimane</td><td>Tollerabilit√†</td><td>Aggiustamento dose</td></tr>
                        <tr><td>4-6 settimane</td><td>Efficacia</td><td>Continuare/modificare</td></tr>
                        <tr><td>3 mesi</td><td>Mantenimento</td><td>Ottimizzazione</td></tr>
                    </table>
                </div>
            </div>

            <div class="alert-box success">
                <strong>Criteri Efficacia:</strong><br>
                ‚úì Riduzione NRS ‚â•30% (minimo significativo)<br>
                ‚úì Riduzione NRS ‚â•50% (sostanzialmente significativo)<br>
                ‚úì Miglioramento qualit√† sonno e funzionalit√†
            </div>
        </div>

        <!-- Scale di Valutazione -->
        <div class="section">
            <h3 style="margin: 0 0 8px 0; color: #2c3e50;">üîπ Scale di Valutazione</h3>
            
            <div class="scale-box">
                <h4 style="margin: 0 0 4px 0;">DN4 - Dolore Neuropatico (Cut-off ‚â•4/10)</h4>
                <p><strong>Sintomi:</strong> Bruciore, freddo doloroso, scosse, formicolio, punture spillo, intorpidimento, prurito<br>
                <strong>Segni:</strong> Ipoestesia tatto/puntura, allodinia</p>
            </div>

            <div class="scale-box">
                <h4 style="margin: 0 0 4px 0;">painDETECT</h4>
                <p><strong>Interpretazione:</strong><br>
                ‚â§12: Improbabile (<15%)<br>
                13-18: Incerto<br>
                ‚â•19: Probabile (>90%)</p>
            </div>

            <div class="scale-box">
                <h4 style="margin: 0 0 4px 0;">NRS - Numerical Rating Scale (0-10)</h4>
                <p>0: Nessun dolore | 1-3: Lieve | 4-6: Moderato | 7-10: Severo</p>
            </div>
        </div>

        <!-- Combinazioni e Casi Speciali -->
        <div class="section">
            <h3 style="margin: 0 0 8px 0; color: #2c3e50;">üîπ Combinazioni Evidence-Based</h3>
            
            <div class="table-container">
                <table>
                    <tr><th>Combinazione</th><th>Razionale</th><th>Dosaggi</th></tr>
                    <tr><td>Pregabalin + Duloxetina</td><td>Meccanismi complementari</td><td>300mg bid + 60mg/die</td></tr>
                    <tr><td>Gabapentin + Amitriptilina</td><td>Sinergia antinocicettiva</td><td>1800mg/die + 75mg sera</td></tr>
                    <tr><td>Topici + Sistemici</td><td>Approccio multimodale</td><td>Secondo protocolli</td></tr>
                </table>
            </div>

            <div class="alert-box">
                <strong>Gestione Effetti Collaterali:</strong><br>
                ‚Ä¢ Sedazione: dose serale, riduzione graduale<br>
                ‚Ä¢ Edemi: diuretici, switch a SNRI<br>
                ‚Ä¢ Aumento peso: dieta, switch a duloxetina<br>
                ‚Ä¢ Nausea: assunzione con cibo, antiemetici
            </div>
        </div>

        <!-- Linee Guida -->
        <div class="section">
            <h3 style="margin: 0 0 8px 0; color: #2c3e50;">üîπ Riferimenti Evidence-Based</h3>
            
            <div class="guidelines-section">
                <h4 style="margin: 0 0 4px 0;">IASP 2024 - Raccomandazioni Chiave</h4>
                <p>‚Ä¢ Approccio multimodale per dolore cronico<br>
                ‚Ä¢ Pregabalin, Gabapentin, Duloxetina prima linea (evidenza forte)<br>
                ‚Ä¢ Personalizzazione basata su fenotipo dolore</p>
            </div>

            <div class="guidelines-section">
                <h4 style="margin: 0 0 4px 0;">EFNS/EAN 2023</h4>
                <p><strong>Livello A:</strong> Pregabalin, Gabapentin, Duloxetina, Amitriptilina<br>
                <strong>Livello B:</strong> Capsaicina 8%, Lidocaina 5%, Tramadolo</p>
            </div>

            <div class="guidelines-section">
                <h4 style="margin: 0 0 4px 0;">NICE Guidelines UK 2023</h4>
                <p>‚Ä¢ Approccio step-wise con valutazione 4-6 settimane<br>
                ‚Ä¢ Tramadolo solo se altri inefficaci<br>
                ‚Ä¢ Riferimento specialistico se resistente</p>
            </div>
        </div>

        <!-- Punti Chiave Riassuntivi -->
        <div class="section">
            <div class="alert-box success">
                <h4 style="margin: 0 0 4px 0;">üéØ Punti Chiave Pratica Clinica</h4>
                <p>1. <strong>Diagnosi:</strong> DN4 ‚â•4, painDETECT ‚â•19<br>
                2. <strong>Prima linea:</strong> Pregabalin, Gabapentin, Duloxetina<br>
                3. <strong>Titolazione:</strong> Graduale, monitoraggio 4-6 settimane<br>
                4. <strong>Target:</strong> Riduzione dolore 30-50%, miglioramento QoL<br>
                5. <strong>Combinazioni:</strong> Se monoterapia insufficiente<br>
                6. <strong>Specialista:</strong> Se inefficacia dopo 2-3 tentativi</p>
            </div>
        </div>

        <!-- Link di ritorno e contatti -->
        <div class="back-link">
            <a href="../index.html">‚Üê Torna all'indice principale</a>
        </div>

        <div class="contatti">

            <p>

                <strong>Contatti:</strong> Per segnalare errori o suggerimenti:<br>

                <span id="email"></span> o <a href="https://matrix.to/#/!TfRAGHjJbrqDqcVaOV:matrix.org/$tpQbM2P8GJgEDd1bN0dOL3VyAKlizj1zFH4-Gqi-_24?via=matrix.org" target="_blank" rel="noopener noreferrer">su Matrix</a> o <a href="https://i.delta.chat/#F545DFAFECB94C1935921435D9ACECCA7504302F&a=dcprns98b%40chatmail.culturanerd.it&g=Neurologia%20per%20schemi&x=Tvb8i9cLX4ZKImLWVUznZTGa&i=8CwDScdUw1wGe0g4hWo2lvRV&s=nzUMeA_XsacHy9LOeyr1l7QT" target="_blank" rel="noopener noreferrer">su Delta Chat</a>

            </p>

            <div class="social-links">

                <a href="https://mastodon.social/@fedele9" target="_blank" rel="noopener noreferrer" class="social-link">

                    <svg width="24" height="24" viewBox="0 0 24 24" fill="#6364FF">

                        <path d="M21.327 8.566c0-4.339-2.843-5.61-2.843-5.61-1.433-.658-3.894-.935-6.451-.956h-.063c-2.557.021-5.016.298-6.45.956 0 0-2.843 1.272-2.843 5.61 0 .993-.019 2.181.012 3.441.103 4.243.778 8.425 4.701 9.463 1.809.479 3.362.579 4.612.51 2.268-.126 3.542-.809 3.542-.809l-.075-1.646s-1.621.511-3.441.449c-1.804-.062-3.707-.194-3.999-2.409a4.523 4.523 0 0 1-.04-.621s1.77.433 4.014.536c1.372.063 2.658-.08 3.965-.236 2.506-.299 4.688-1.843 4.962-3.254.434-2.223.398-5.424.398-5.424zm-3.353 5.59h-2.081V9.057c0-1.075-.452-1.62-1.357-1.62-1 0-1.501.647-1.501 1.927v2.791h-2.069V9.364c0-1.28-.501-1.927-1.502-1.927-.905 0-1.357.545-1.357 1.62v5.099H6.026V8.903c0-1.074.273-1.927.823-2.558.566-.631 1.307-.955 2.228-.955.892 0 1.58.343 2.077 1.032l.451.757.452-.757c.497-.689 1.185-1.032 2.077-1.032.92 0 1.662.324 2.228.955.55.631.823 1.484.823 2.558v5.253z"/>

                    </svg>

                    Mastodon

                </a>

                <a href="https://gram.social/Fedele" target="_blank" rel="noopener noreferrer" class="social-link">

                    <svg width="24" height="24" viewBox="0 0 24 24" fill="#E1306C">

                        <path d="M12 2c5.523 0 10 4.477 10 10s-4.477 10-10 10S2 17.523 2 12 6.477 2 12 2zm1.031 6.099h-2.624c-.988 0-1.789.776-1.789 1.733v6.748l2.595-2.471h1.818c1.713 0 3.101-1.345 3.101-3.005s-1.388-3.005-3.1-3.005z"/>

                    </svg>

                    Pixelfed

                </a>

                

                <a href="https://github.com/fedele93" target="_blank" rel="noopener noreferrer" class="social-link">

                    <svg width="24" height="24" viewBox="0 0 24 24" fill="#000">

                        <path d="M12 0c-6.626 0-12 5.373-12 12 0 5.302 3.438 9.8 8.207 11.387.599.111.793-.261.793-.577v-2.234c-3.338.726-4.033-1.416-4.033-1.416-.546-1.387-1.333-1.756-1.333-1.756-1.089-.745.083-.729.083-.729 1.205.084 1.839 1.237 1.839 1.237 1.07 1.834 2.807 1.304 3.492.997.107-.775.418-1.305.762-1.604-2.665-.305-5.467-1.334-5.467-5.931 0-1.311.469-2.381 1.236-3.221-.124-.303-.535-1.524.117-3.176 0 0 1.008-.322 3.301 1.23.957-.266 1.983-.399 3.003-.404 1.02.005 2.047.138 3.006.404 2.291-1.552 3.297-1.23 3.297-1.23.653 1.653.242 2.874.118 3.176.77.84 1.235 1.911 1.235 3.221 0 4.609-2.807 5.624-5.479 5.921.43.372.823 1.102.823 2.222v3.293c0 .319.192.694.801.576 4.765-1.589 8.199-6.086 8.199-11.386 0-6.627-5.373-12-12-12z"/>

                    </svg>

                    GitHub

                </a>

                <a href="https://matrix.to/#/!TfRAGHjJbrqDqcVaOV:matrix.org/$tpQbM2P8GJgEDd1bN0dOL3VyAKlizj1zFH4-Gqi-_24?via=matrix.org" target="_blank" rel="noopener noreferrer" class="social-link">

                    <svg width="24" height="24" viewBox="0 0 24 24" fill="#000">

                        <path d="M.632.55v22.9H2.28V24H0V0h2.28v.55zm7.043 7.26v1.157h.033c.309-.443.683-.784 1.117-1.024.433-.245.936-.365 1.5-.365.54 0 1.033.107 1.481.314.448.208.785.582 1.02 1.108.254-.374.6-.706 1.034-.992.434-.287.95-.43 1.546-.43.453 0 .872.056 1.26.167.388.11.716.286.993.53.276.245.489.559.646.951.152.392.23.863.23 1.417v5.728h-2.349V11.52c0-.286-.01-.559-.032-.812a1.755 1.755 0 0 0-.18-.66 1.106 1.106 0 0 0-.438-.448c-.194-.11-.457-.166-.785-.166-.332 0-.6.064-.803.189a1.38 1.38 0 0 0-.48.499 1.946 1.946 0 0 0-.231.696 5.56 5.56 0 0 0-.06.785v4.768h-2.35v-4.8c0-.254-.004-.503-.018-.752a2.074 2.074 0 0 0-.143-.688 1.052 1.052 0 0 0-.415-.503c-.194-.125-.476-.19-.854-.19-.111 0-.259.024-.439.074-.18.051-.36.143-.53.282-.171.138-.319.337-.439.595-.12.259-.18.6-.18 1.02v4.966H5.46V7.81zm15.693 15.64V.55H21.72V0H24v24h-2.28v-.55z"/>

                    </svg>

                    Matrix

                </a>

            </div>

        </div>

    </div>

<script>

        // Email mascherata

        const nome = "neurologiaperschemi.wolf853";      

        const dominio = "passinbox.com"; 

        const email = nome + "@" + dominio;

        document.getElementById("email").innerHTML = `<a href="mailto:${email}">${email}</a>`;

</script>

    <script>

  if ('serviceWorker' in navigator) {

    window.addEventListener('load', () => {

      navigator.serviceWorker.register('sw.js')

        .then((registration) => {

          console.log('ServiceWorker registrato con successo!');

        })

        .catch((error) => {

          console.log('Errore nella registrazione:', error);

        });

    });

  }

</script>
</body>
</html>
